Shots:

• The P-III REACH 2 study involves assessing of Cyramza + best supportive care (BSC) vs PBO + BSC in 292 patients with high alpha fetoprotein (AFP-High) >400ng/ml (HCC)- who were intolerant to- or who had disease progression while on or following treatment with sorafenib
• P-III REACH 2 study results: 1EP@ mOS (8.5 vs 7.3mos); 2EP@ mPFS (2.8 vs 1.6mos); ORR (4.6% vs 1.1%); Disease Control Rate (ORR + stable disease) (59.9% vs 38.9%); pooled results: OS (8.1 vs 5.0mos)- Presented in ASCO 2018
• Cyramza is a VEGF Receptor 2 antagonist serving as an antiangiogenic therapy- indicated as monothx or in combination with paclitaxel & docetaxel for metastatic gastric & metastatic NSCLC respectively. The company has filled its BLA in the US- EU & Japan

Ref: Eli Lilly | Image: Eli Lilly